仙灵强骨口服液；_骨质疏松；_维甲酸_

仙灵强骨口服液对维甲酸诱导大鼠骨质疏松症的治疗作用

http://www.100md.com 《时珍国医国药》 2007年第1期

仙灵强骨口服液；,骨质疏松；,维甲酸,,仙灵强骨口服液；,骨质疏松；,维甲酸,1材料与方法,2结果,3讨论,参考文献：

     摘要：目的观察仙灵强骨口服液对维甲酸诱导大鼠骨质疏松症的治疗作用。方法70 mg/kg维甲酸连续灌胃45 d，诱导雄性大鼠形成骨质疏松模型。成功造模后随机将大鼠分为强骨口服液高、中、低剂量组和阳性药组、模型组，另设正常对照组，开始给药。给药45 d后收集血液分离血清测定碱性磷酸酶(ALP)、抗酒石酸酸性磷酸酶(StrACP)，分离大鼠双侧股骨，测定股骨骨参数。结果仙灵强骨口服液对大鼠血清ALP水平、StrACP水平、骨密度、骨矿含量均有改善作用。结论仙灵强骨口服液对维甲酸所致大鼠骨质疏松症有治疗作用。

    关键词：仙灵强骨口服液；骨质疏松；维甲酸

    Effect of Xianlingqianggukoufuye on Osteoporosis Rats Induced by Retinoic Acid

    WANG Dongchun， TAN Aimin， MA Shiping， LIU Kang

    (Jiangsu Simcere Pharmaceutical Research Company Ltd, Nanjing 210042,China； China Pharmaceutical University , Nanjing 210038,China)

    Abstract：ObjectiveTo study the effects of Xianlingqianggukoufuye(XLQGKFY) on osteoporosis rats induced by retinoic acid MethodsThe osteoporosis of rats was induced by administering 70 mg/kg retinoic acid for 45 days. Rats were randomly divided into 5 groups: osteoporosis (OP), OP+Etidronate Disodiuml, OP+XLQGKFY(high dose, middle dose, low dose), the others were control group, and treated with drugs. Double in vivo fluorochrome labeling was administered to all rats. At the end-point of study, the blood was collected to detect contents of ALP, ACP in serum, femur bone sections were cut for BMP analysis. ResultsXLQGKFY decreased the StrACP, increased StrACP and BMP. ConclusionXianlingqianggukoufuye has a curative effect on osteoporosis,which provides theoretic basis for clinical use. ......

百拇医药网 http://www.100md.com/html/DirDu/2007/04/28/43/01/55.htm

您现在查看是摘要页，全文长 6898 字符。